Tellihealth

Tellihealth

Accuhealth Technologies builds and operates the backend for remote patient monitoring — shipping cellular-enabled blood pressure cuffs, glucose meters, and pulse oximeters to patients, then staffing the nurses who triage the incoming data. Founded in the Rio Grande Valley, the firm concentrates on the operational heavy lifting that most physician groups lack the headcount to manage internally. Its platform integrates with major electronic health record systems so that abnormal readings generate actionable flags inside a doctor's existing workflow rather than a separate portal. The firm's model blends a hardware supply chain with a recurring clinical-services revenue stream. Practices pay Accuhealth to handle device logistics, patient onboarding, and 24/7 nurse monitoring, while the practice bills Medicare and private payers for the remote monitoring codes. Confirmed clients include primary care groups, cardiology practices, and multi-specialty clinics across Texas and the southeastern United States. The firm has expanded its footprint by partnering with accountable care organizations and federally qualified health centers that carry high-risk patient panels. Accuhealth's differentiation lies in owning the nursing triage layer rather than licensing software alone. Competitors often sell a dashboard and leave the clinic to staff the monitoring; Accuhealth employs the nurses who call patients when readings spike. That structure makes its revenue stickier — unplugging from Accuhealth means a practice must hire overnight clinical staff. The firm has grown organically, with no publicly disclosed venture rounds, adding patients primarily through direct sales to regional health systems. Remote patient monitoring reimbursement expanded during the COVID-19 public health emergency and was subsequently locked into the Medicare Physician Fee Schedule, creating a structural tailwind for firms like Accuhealth. The company's geographic base in McAllen — a market with elevated chronic disease prevalence — provides a natural laboratory for demonstrating outcomes. Its governance and capital structure remain opaque, with no named principals or disclosed investors in public filings.